NASDAQ:OCGN Ocugen - OCGN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.29 -0.04 (-3.01%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.27▼$1.3550-Day Range$1.11▼$1.6152-Week Range$1.09▼$4.53Volume4.98 million shsAverage Volume6.53 million shsMarket Capitalization$282.37 millionP/E RatioN/ADividend YieldN/APrice Target$5.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Ocugen MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside318.6% Upside$5.40 Price TargetShort InterestBearish20.37% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 5 Articles This WeekInsider TradingSelling Shares$128,000 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.39) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.60 out of 5 starsMedical Sector880th out of 1,028 stocksBiological Products, Except Diagnostic Industry139th out of 168 stocks 3.4 Analyst's Opinion Consensus RatingOcugen has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.40, Ocugen has a forecasted upside of 318.6% from its current price of $1.29.Amount of Analyst CoverageOcugen has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted20.37% of the outstanding shares of Ocugen have been sold short.Short Interest Ratio / Days to CoverOcugen has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Ocugen has recently increased by 9.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOcugen does not currently pay a dividend.Dividend GrowthOcugen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCGN. Previous Next 2.3 News and Social Media Coverage News SentimentOcugen has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Ocugen this week, compared to 5 articles on an average week.Search Interest32 people have searched for OCGN on MarketBeat in the last 30 days. This is an increase of 45% compared to the previous 30 days.MarketBeat Follows10 people have added Ocugen to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ocugen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $128,000.00 in company stock.Percentage Held by InsidersOnly 2.81% of the stock of Ocugen is held by insiders.Percentage Held by InstitutionsOnly 37.54% of the stock of Ocugen is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ocugen are expected to decrease in the coming year, from ($0.39) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocugen is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocugen is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcugen has a P/B Ratio of 2.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ocugen (NASDAQ:OCGN) StockOcugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.Read More Receive OCGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter. Email Address OCGN Stock News HeadlinesFebruary 4, 2023 | finance.yahoo.com1 Reason to Buy Ocugen in 2023 and 2 Reasons to SellFebruary 1, 2023 | finance.yahoo.comOcugen Appoints Quan A. Vu as Chief Business OfficerFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 31, 2023 | marketwatch.comOcugen Inc. stock rises Tuesday, outperforms marketJanuary 31, 2023 | finance.yahoo.comOcugen, Inc. to Present at 2023 BIO CEO & Investor ConferenceJanuary 18, 2023 | seekingalpha.comOcugen: FDA Sector Head States Bridging Studies InsufficientJanuary 17, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Buy Rating on Ocugen (OCGN)January 17, 2023 | markets.businessinsider.comNoble Financial Reaffirms Their Buy Rating on Ocugen (OCGN)February 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 9, 2023 | finance.yahoo.comOcugen Announces Encouraging Data From Late-Stage COVID-19 Vaccine StudyDecember 29, 2022 | finance.yahoo.comWhy Shares of Ocugen Jumped ThursdayDecember 15, 2022 | finance.yahoo.comOcugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital AmaurosisDecember 13, 2022 | finance.yahoo.comOcugen, Inc. to Ring the Nasdaq Stock Market Closing BellDecember 7, 2022 | finance.yahoo.comOcugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital AmaurosisNovember 28, 2022 | finance.yahoo.comOcugen to Present at 3rd Annual Dry AMD Therapeutics SummitNovember 9, 2022 | finance.yahoo.comWhy Ocugen Stock Wilted on WednesdayNovember 8, 2022 | finance.yahoo.comOcugen Provides Business Update & Third Quarter 2022 Financial ResultsNovember 7, 2022 | finance.yahoo.comOcugen, Inc.'s (NASDAQ:OCGN) largest shareholders are individual investors with 58% ownership, institutions own 40%October 27, 2022 | finance.yahoo.comOcugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial ResultsOctober 20, 2022 | finance.yahoo.comOcugen to Host R&D Day in New York City on Tuesday, November 1, 2022 - Yahoo FinanceOctober 19, 2022 | globenewswire.comOcugen to Host R&D Day in New York City on Tuesday, November 1, 2022 - GlobeNewswireOctober 19, 2022 | finance.yahoo.comOcugen to Host R&D Day in New York City on Tuesday, November 1, 2022October 14, 2022 | globenewswire.comOcugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2 - GlobeNewswireOctober 13, 2022 | finance.yahoo.comOcugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2 - Yahoo FinanceOctober 12, 2022 | finance.yahoo.comOcugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2October 7, 2022 | finance.yahoo.comOcugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences - Yahoo FinanceOctober 6, 2022 | fool.comWall Street Thinks This Top 100 Robinhood Stock Could Skyrocket by 217% - The Motley FoolSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OCGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter. Email Address OCGN Company Calendar Last Earnings11/08/2022Today2/05/2023Next Earnings (Estimated)2/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OCGN CUSIPN/A CIK1372299 Webocugen.com Phone(484) 328-4701Fax781-547-4452Employees56Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.40 High Stock Price Forecast$8.00 Low Stock Price Forecast$3.50 Forecasted Upside/Downside+318.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.83% Return on Assets-59.94% Debt Debt-to-Equity Ratio0.02 Current Ratio7.21 Quick Ratio7.21 Sales & Book Value Annual Sales$42.62 million Price / Sales6.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book2.69Miscellaneous Outstanding Shares218,890,000Free Float212,736,000Market Cap$282.37 million OptionableNot Optionable Beta3.85 Key ExecutivesShankar MusunuriChairman & Chief Executive OfficerJessica CrespoCFO, Chief Accounting Officer & SVP-FinanceArun UpadhyayChief Scientific OfficerRobert J. HopkinsChief Medical OfficerNirdosh JagotaSVP-Regulatory Affairs, Compliance & SafetyKey CompetitorsVectivBioNASDAQ:VECTInnate PharmaNASDAQ:IPHAGritstone bioNASDAQ:GRTSAdaptimmune TherapeuticsNASDAQ:ADAPAcumen PharmaceuticalsNASDAQ:ABOSView All CompetitorsInsiders & InstitutionsBank of Montreal CanBought 4,600 shares on 2/1/2023Ownership: 0.000%Shankar MusunuriSold 100,000 sharesTotal: $128,000.00 ($1.28/share)Bank of New York Mellon CorpBought 63,095 shares on 12/8/2022Ownership: 0.439%BNP Paribas Arbitrage SNCBought 584,292 shares on 11/16/2022Ownership: 0.267%Jane Street Group LLCSold 43,500 shares on 11/16/2022Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions OCGN Stock - Frequently Asked Questions Should I buy or sell Ocugen stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OCGN shares. View OCGN analyst ratings or view top-rated stocks. What is Ocugen's stock price forecast for 2023? 5 analysts have issued 12-month price targets for Ocugen's shares. Their OCGN share price forecasts range from $3.50 to $8.00. On average, they expect the company's share price to reach $5.40 in the next year. This suggests a possible upside of 318.6% from the stock's current price. View analysts price targets for OCGN or view top-rated stocks among Wall Street analysts. How have OCGN shares performed in 2023? Ocugen's stock was trading at $1.30 at the start of the year. Since then, OCGN shares have decreased by 0.8% and is now trading at $1.29. View the best growth stocks for 2023 here. When is Ocugen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023. View our OCGN earnings forecast. How were Ocugen's earnings last quarter? Ocugen, Inc. (NASDAQ:OCGN) released its quarterly earnings data on Tuesday, November, 8th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). What other stocks do shareholders of Ocugen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ocugen investors own include Onconova Therapeutics (ONTX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), FuelCell Energy (FCEL), Biocept (BIOC), OPKO Health (OPK), Tonix Pharmaceuticals (TNXP), Actinium Pharmaceuticals (ATNM) and Carnival Co. & (CCL). What is Ocugen's stock symbol? Ocugen trades on the NASDAQ under the ticker symbol "OCGN." Who are Ocugen's major shareholders? Ocugen's stock is owned by many different retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher Dold, Daniel Purefoy, Junge Zhang, Kirsten Castillo, Manish Potti, Prabhavathi Fernandes, Ramesh Kumar, Sanjay Subramanian, Shankar Musunuri, Uday Kompella and Vijay Tammara. View institutional ownership trends. How do I buy shares of Ocugen? Shares of OCGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ocugen's stock price today? One share of OCGN stock can currently be purchased for approximately $1.29. How much money does Ocugen make? Ocugen (NASDAQ:OCGN) has a market capitalization of $282.37 million and generates $42.62 million in revenue each year. The company earns $-58,370,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. How can I contact Ocugen? Ocugen's mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The official website for the company is ocugen.com. The company can be reached via phone at (484) 328-4701, via email at ir@ocugen.com, or via fax at 781-547-4452. This page (NASDAQ:OCGN) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.